Bluejay Diagnostics, Inc. (BJDX)

Bluejay Diagnostics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	0.25	-	-
Cost of Revenue	-	-	0.2	-	-
Gross Profit	-	-	0.05	-	-
Selling, General & Admin	3.7	4.6	5.21	2.08	0.67
Research & Development	3.47	5.71	4.15	1.15	0.53
Operating Expenses	7.17	10.31	9.37	3.23	1.2
Operating Income	-7.17	-10.31	-9.32	-3.23	-1.2
Interest Expense	-0.82	-	-	-0.51	-0.14
Interest & Investment Income	0.15	0.16	0.09	-	-
Other Non Operating Income (Expenses)	0.13	0.19	0.17	0.25	0.08
EBT Excluding Unusual Items	-7.72	-9.95	-9.06	-3.49	-1.26
Asset Writedown	-	-	-0.24	-	-
Other Unusual Items	-	-	-	0.01	0.1
Pretax Income	-7.72	-9.95	-9.3	-3.49	-1.16
Net Income	-7.72	-9.95	-9.3	-3.49	-1.16
Preferred Dividends & Other Adjustments	13.22	-	-	-	-
Net Income to Common	-20.94	-9.95	-9.3	-3.49	-1.16
Shares Outstanding (Basic)	0	-	-	-	-
Shares Outstanding (Diluted)	0	-	-	-	-
EPS (Basic)	-114.19	-	-	-	-
EPS (Diluted)	-114.19	-	-	-	-
Free Cash Flow	-8.13	-9.02	-8.94	-4.39	-0.51
Free Cash Flow Per Share	-44.31	-	-	-	-
Gross Margin	-	-	19.64%	-	-
Operating Margin	-	-	-3741.48%	-	-
Profit Margin	-	-	-3733.11%	-	-
Free Cash Flow Margin	-	-	-3590.13%	-	-
EBITDA	-7.09	-9.66	-9.16	-3.08	-1.04
D&A For EBITDA	0.08	0.65	0.16	0.15	0.16
EBIT	-7.17	-10.31	-9.32	-3.23	-1.2

Updated Nov 7, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q